Vijay Modur - Dec 1, 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Role
HEAD OF R&D
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact
Stock symbol
ELOX
Transactions as of
Dec 1, 2021
Transactions value $
-$46,349
Form type
4
Date filed
12/3/2021, 04:14 PM
Previous filing
May 18, 2021
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELOX Common Stock Options Exercise $0 +219K $0.00 219K Dec 1, 2021 Direct F1
transaction ELOX Common Stock Tax liability -$46.3K -64.4K -29.35% $0.72 155K Dec 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Restricted Stock Units Options Exercise $0 -219K -100% $0.00* 0 Dec 1, 2021 Common Stock 219K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.